Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 753718 | ISIN: US98956P1021 | Ticker-Symbol: ZIM
Tradegate
16.02.26 | 09:30
81,76 Euro
+0,66 % +0,54
Branche
Gesundheitswesen
Aktienmarkt
S&P 500
1-Jahres-Chart
ZIMMER BIOMET HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ZIMMER BIOMET HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
80,9281,5418:48
80,9281,5418:30
PR Newswire
259 Leser
Artikel bewerten:
(1)

Zimmer Biomet Holdings, Inc.: Zimmer Biomet Announces New Chief Medical Advisors to Help Improve Standard of Musculoskeletal Care

Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants

Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.)

WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience to help guide the Company's new product pipeline and portfolio strategy across their respective areas of focus, and enhance Zimmer Biomet's medical education initiatives.

Dr. Vigdorchik is a board-certified, fellowship-trained orthopaedic surgeon at Hospital for Special Surgery (HSS) in New York City, specializing in hip and knee replacement surgery. Dr. Murthi is a board-certified, fellowship-trained orthopaedic surgeon who serves as Chief of Shoulder and Elbow Surgery and Director of the Shoulder and Elbow Fellowship Program at MedStar Union Memorial Hospital in Baltimore, Md.

"These appointments reflect Zimmer Biomet's commitment to deepening clinical collaboration and accelerating advancements across our portfolio - from implants and robotic technology to sports medicine and extremities," said Ivan Tornos, Chairman, President and Chief Executive Officer, Zimmer Biomet. "We're proud to welcome them both as strategic partners in helping to redefine the future of musculoskeletal care."

In these roles, Drs. Vigdorchik and Murthi will assist with our medical education and surgeon engagement; advise on the Company's technology and implant strategy and development roadmap; and serve as strategic liaisons between Zimmer Biomet and the broader surgical community.

About Dr. Jonathan M. Vigdorchik
Dr. Vigdorchik holds several prominent academic and clinical leadership positions, including serving as Division Chief of Adult Reconstruction and Joint Replacement at HSS and Director of Bone Implant Longevity Research at HSS's Griffin Research Accelerator. In addition, he is currently an Associate Professor of Orthopaedic Surgery at Weill Cornell Medical College. He is active in professional societies including The Hip Society, The Knee Society, the American Academy of Orthopaedic Surgeons (AAOS) and the American Association of Hip and Knee Surgeons (AAHKS), where he currently serves as the Education and Communications Council Chair and earlier served as Program Chair for the 2024 AAHKS Annual Meeting.

Dr. Vigdorchik earned his medical degree from the University of Missouri - Columbia School of Medicine, completed his orthopaedic surgery residency at the Detroit Medical Center / Providence Hospital, and received fellowship training in Adult Reconstruction and Joint Replacement at HSS. He also completed an international traveling fellowship in hip preservation surgery with training at centers in Switzerland, Boston Children's Hospital, and Washington University in St. Louis.

Tornos said, "Dr. Vigdorchik is one of the most well-known, well-respected and well-published voices in orthopedics today. As a leading surgeon, clinical educator and true innovator, he brings an invaluable combination of experience and insight to this role. We are excited to partner with him as we continue to accelerate advancements in AI, smart implants, robotics and digital technologies that are redefining joint replacement care."

"I'm honored to take on this role with Zimmer Biomet at such an exciting time in the evolution of orthopedic care," said Dr. Vigdorchik. "We're at the intersection of AI, powerful digital technologies and advanced implants that together have the potential to dramatically improve outcomes and personalize care for each patient. I look forward to partnering with the Zimmer Biomet team to help shape the future of joint replacement."

About Dr. Anand M. Murthi
In addition to his role at MedStar, Dr. Murthi is also a Professor of Orthopaedic Surgery at Georgetown University School of Medicine. He is globally recognized for his expertise as an active surgeon, innovator, and pioneer in surgical techniques and device design. He is a founding member of prestigious societies including the Association of Clinical Elbow and Shoulder Surgeons (ACESS), Indian American Shoulder & Elbow Surgeons (IASES), and an active member of American Shoulder and Elbow Surgeons (ASES), where he established the Mentorship Program, chaired the Educational Committee, and was recently elected to the Neer Circle. He also serves as Co-Chairman of the Mid-Atlantic Shoulder and Elbow Society and the Orthopaedic Summit and Emerging Technologies Conference, while remaining a highly sought-after speaker and faculty member at major U.S. and international meetings. He is the Editor-in-Chief of Current Orthopaedic Practice Journal. He is also the co-designer of Shoulder JAM by OBERD, the first international shoulder data registry.

Dr. Murthi received his medical degree from Case Western Reserve University School of Medicine and completed his general surgery internship and orthopaedic surgery residency at George Washington University Medical Center. He completed a fellowship in shoulder and elbow reconstruction at the New York Orthopaedic Hospital - Columbia Presbyterian Medical Center.

Tornos said, "Dr. Murthi brings deep clinical expertise, a proven track record of innovation, and visionary leadership in surgical techniques and device design. His partnership will be instrumental as we continue to accelerate growth across our S.E.T. business. With his influence and insight, Zimmer Biomet will further solidify our position as a trusted partner in delivering customer-centric solutions."

"Throughout my career, I've been driven by a passion for advancing surgical techniques and designing intelligent technologies that raise the standard of care in shoulder and elbow surgery," said Dr. Murthi. "I'm thrilled to join the Zimmer Biomet team-a team equally dedicated to innovation. Together, we have a remarkable opportunity to redefine what's possible in musculoskeletal care and deliver transformative solutions to surgeons and patients worldwide."

About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.x.com/zimmerbiomet.

Zimmer Biomet:


Media


Investors


Kristen Cardillo


David DeMartino


925-786-4913


646-531-6115


[email protected]


[email protected]






Kirsten Fallon


Zach Weiner


781-779-5561


908-591-6955


[email protected]


[email protected]

SOURCE Zimmer Biomet Holdings, Inc.

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.